Company CVAbout Godavari Drugs Ltd 
Godavari Drugs Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, through its manufacturing facility at Nanded, Maharashtra, India.
Company Coordinates
Company Details
Mayfair 1-8-303-34, Sardar Patel Road Secunderabad Andhra Pradesh : 500003
Registrar Details
Cil Securities Ltd , 214 Raghava Ratna Towers , Chirag Ali Lane, Abidas, Hyderabad
Capital StructureCapital Structure
Present Equity Capital
INR 7.53 Cr
Number of Shares
75.31 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
10-Aug-2009
75.31
7.53
375000
10
Allotment of Equity Shares To Promoter & Others
10-Aug-2009
75.31
7.53
375000
10
Allotment of Equity Shares To Promoter & Others
03-Apr-2007
71.56
7.16
375000
10
Conversion of Warrants
03-Apr-2007
71.56
7.16
375000
10
Conversion of Warrants
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
0.2153
Mutual Funds
Held by 0 Schemes
FIIs
Held by 0 FIIs
Promoter with highest holding
Sushma Kakani (15.34%)
Highest Public shareholder
Highcrestt Global Company Ltd (2.66%)
Individual Investors Holdings
37.05%
Board of Directors
Management
Designation
Remuneration
Mukund Kakani
Managing Director
17.01 lacs
S A Hussain
Non-Exec. & Independent Dir.
80.0 k
Mohit Jaju
Whole Time Director & CFO
16.48 lacs
Ramesh Babu Telugu
Non-Exec. & Independent Dir.
80.0 k
Vimala B Madon
Non-Exec. & Independent Dir.
80.0 k
Ghanshyam Jaju
Chairman (Non-Executive)
0
Mahindra Uday Bhalerao
Non Executive Director
20.0 k
Venkatesh Achanta
Company Sec. & Compli. Officer
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Bulk Drugs (Own Production)
83.54
100.00%
Bulk Drugs (Own Production)
Stock DNARevenue and Profits:
Net Sales:
27 Cr
(Quarterly Results - Sep 2025)
Net Profit:
1 Cr
Pharmaceuticals & Biotechnology
INR 56 Cr (Micro Cap)
15.00
27
0.00%
1.37
8.54%
1.32
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
